Ibrutinib dose modifications in the management of CLL.

ABSTRACT:

Background

Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) in 2014. Ibrutinib is often used to treat patients who are younger than the patients originally included in theclinical trials have additional unfavorable prognostic factors and suffer from additional comorbidities excluded from the original phase III trials. Our objective was to examine current clinical practices and their impact in this expanded population of CLL patients who often require adjustments in the standard prescribed dose and schedule of therapy.

Materials and methods

An extensive review of the medical literature was conducted to establish the consensus on ibrutinib dose modifications in patients with CLL. Twenty-nine studies were reviewed

SUBMITTER: Hardy-Abeloos C 

PROVIDER: S-EPMC7275592 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature